Research context
What is retatrutide?
Retatrutide is an investigational peptide studied as a triple hormone-receptor agonist. The published phase 2 trial describes activity at GIP, GLP-1, and glucagon receptors.
Current regulatory status
Retatrutide is not an FDA-approved drug. FDA states that retatrutide cannot be used in compounding under federal law and that it has not been found safe and effective for any condition. That is why a research-supplier listing should not be treated as a medical product listing.
Why it appears on a sourcing-comparison site
The comparison table is limited to vendor-stated fields: package, listed price, payment availability, and reported COA documentation. It is a record of what the vendors list. It does not interpret research results, provide dosing, or recommend use.